We have created proprietary circular RNA platform with the aim of developing cost-effective and accessible novel RNA products. Millions of patients’ lives could be impacted by second generation RNA products.
2020 was a breakout year for RNA technology platform with the launch of RNA vaccines. RNA is a non-infectious, non-integrating platform amenable to small footprint manufacturing, which can be rapidly and inexpensively scaled up. The first-generation RNA technology based on linear non-replicating RNA face the challenges of high cost, ultra-cold chain requirement, and low protein expression appropriate for the development of prophylactic vaccines. Our second generation circular RNA platform, addresses challenges related to cost, dose, reagent availability, temperature stability, and delivery. which is applicable across different areas of vaccine and therapeutics development.
2020 was a breakout year for RNA technology platform with the launch of RNA vaccines. RNA is a non-infectious, non-integrating platform amenable to small footprint manufacturing, which can be rapidly and inexpensively scaled up. The first-generation RNA technology based on linear non-replicating RNA face the challenges of high cost, ultra-cold chain requirement, and low protein expression appropriate for the development of prophylactic vaccines.
Our second generation circular RNA platform, addresses challenges related to cost, dose, reagent availability, temperature stability, and delivery. which is applicable across different areas of vaccine and therapeutics development.
Circular RNA confers stability to the normally labile RNA molecule. This allows for elimination of the need for ultra cold-chain infrastructure, thereby reducing cost and improving access.
We have established an efficient methodology to create scarless and cost effective circular RNA. Enhanced protein expression, which is independent of the capping reagent, enhances the usefulness of the
platform.
Despite applications in areas such as oncology, metabolic or CNS diseases, the global uptake of biologics is stunted due to high costs. RNA could provide a viable alternative route for biologics by using our own cells as “bio-reactors”. Circular RNA with its advantages represents the most promising route to achieve this larger aim, impacting millions of patients’ lives.
Circular RNA confers stability to the normally labile RNA molecule. This allows for elimination of the need for ultra cold-chain infrastructure, thereby reducing cost and improving access.
We have established an efficient methodology to create scarless and
cost effective circular RNA. Enhanced protein expression, which is
independent of the capping reagent, enhances the usefulness of the
platform.
Despite applications in areas such as oncology, metabolic or CNS diseases, the global uptake of biologics is stunted due to high costs. RNA could provide a viable alternative route for biologics by using our own cells as “bio-reactors”. Circular RNA with its advantages represents the most promising route to achieve this larger aim, impacting millions of patients’ lives.
